I-ne CO (4933) Q3 2026 earnings summary

Executive summary

• 9M net sales rose 24.6% YoY to ¥42,814M; EBITDA declined 4.3% to ¥3,355M and operating profit fell 8.8% to ¥2,013M.

• Growth was led by Beauty Devices and Skincare and Others; FY2026 net sales guidance was raised to ¥58,000–59,000M.

Financial highlights

• 9M gross profit increased to ¥25,540M from ¥19,803M, while SG&A rose to ¥23,526M from ¥17,595M.

• Ordinary profit fell 10.5% to ¥1,889M; profit attributable to owners declined 15.7% to ¥932M from ¥1,105M, and basic EPS was ¥52.42 vs. ¥63.24.

• Additional advertising and promotional investment totaled ¥2.5bn in 9M to accelerate top-line growth.

Outlook and guidance

• FY2026 net sales forecast raised from ¥55.0–57.0bn to ¥58.0–59.0bn; EBITDA forecast raised at the lower end to ¥2.2–3.2bn and operating profit to ¥0.5–1.5bn, with upper ends unchanged.

• The FY2026 forecast implies EBITDA down 43.1%–60.9% and operating profit down 61.3%–87.1% YoY.

• Continued upfront investment, particularly in health foods, is intended to support growth in FY2027 and beyond.

• FY2026 annual dividend forecast remains ¥15 per share, comprising ¥7 interim and ¥8 year-end.